Current Report Filing (8-k)
07 January 2017 - 8:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 6, 2017
ONCOGENEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
033-80623
|
|
95-4343413
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
19820 North Creek Parkway
Bothell, Washington
|
|
98011
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (425)
686-1500
N/A
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☒
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Attached hereto as Exhibit 99.1 is an investor presentation that Achieve Life Science,
Inc. (Achieve) plans to present during the J.P. Morgan Healthcare Conference.
Item 9.01
|
Financial Statements and Exhibits.
|
Reference is made to the Exhibit Index included with this Current
Report on Form
8-K.
Important Additional Information about the Proposed Merger
This communication is being made in respect of the proposed merger involving OncoGenex Pharmaceuticals, Inc. (OncoGenex) and Achieve. OncoGenex
intends to file a registration statement on Form
S-4
with the SEC, which will contain a joint proxy statement/prospectus and other relevant materials, and plans to file with the Securities and Exchange
Commission (SEC) other documents regarding the proposed transaction. The final joint proxy statement/prospectus will be sent to the stockholders of OncoGenex and Achieve. The joint proxy statement/prospectus will contain information
about OncoGenex, Achieve, the proposed merger and related matters.
Stockholders are urged to read the joint proxy statement/prospectus (including any amendments or supplements) and other documents filed with the SEC carefully in their entirety
when they become available, as they will contain important information that stockholders should consider before making a decision about the merger and related matters.
In addition to receiving the joint proxy statement/prospectus and
proxy card by mail, stockholders will also be able to obtain the joint proxy statement/prospectus, as well as other filings containing information about OncoGenex, without charge, from the SECs website (http://www.sec.gov) or, without charge,
by directing a written request to: OncoGenex Pharmaceuticals, Inc., 19820 North Creek Parkway, Suite 201, Bothell, WA 98011, Attention: Investor Relations or to Achieve Life Science, Inc., 30 Sunnyside Avenue, Mill Valley, CA 94941,
Attention: Rick Stewart.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No
offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in Solicitation
OncoGenex and its executive
officers and directors may be deemed to be participants in the solicitation of proxies from OncoGenexs stockholders with respect to the matters relating to the proposed merger. Achieve and its officers and directors may also be deemed a
participant in such solicitation. Information regarding OncoGenexs executive officers and directors is available in OncoGenexs proxy statement on Schedule 14A, filed with the SEC on April 21, 2016. Information regarding any interest
that OncoGenex, Achieve or any of the executive officers or directors of OncoGenex or Achieve may have in the transaction with Achieve will be set forth in the joint proxy statement/prospectus that OncoGenex intends to file with the SEC in
connection with its stockholder vote on matters relating to the proposed merger. Stockholders will be able to obtain this information by reading the joint proxy statement/prospectus when it becomes available.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ONCOGENEX PHARMACEUTICALS, INC.
|
|
|
|
Date: January 6, 2017
|
|
|
|
/s/ John Bencich
|
|
|
|
|
John Bencich
|
|
|
|
|
Chief Financial Officer
|
3
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Achieve Life Science, Inc. Investor Presentation
|
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Apr 2024 to May 2024
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From May 2023 to May 2024